Related Experiment Video
Updated: Mar 9, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Optimal antithrombotic strategies in atrial fibrillation patients undergoing PCI: A network meta-analysis of
Mustafa Abomohsen1, Mohamed Rifai2, Mohamed S Elgendy3
1Cardiology Department, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Insights
A de-escalation strategy (short-course dual therapy followed by DOAC monotherapy) may reduce bleeding in atrial fibrillation patients undergoing PCI. However, warfarin-based regimens significantly increase bleeding and intracranial hemorrhage risks.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Managing antithrombotic therapy in atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or coronary artery disease (CAD) is complex due to competing bleeding and ischemic risks.
- Five antithrombotic strategies were compared: de-escalation, VKA triple therapy, VKA dual therapy, DOAC dual therapy, and DOAC triple therapy.
Purpose of the Study:
- To compare the efficacy and safety of five different antithrombotic strategies in patients with AF undergoing PCI.
- To evaluate risks of all-cause death and bleeding events across various treatment regimens.
Main Methods:
- A systematic literature search was conducted across major databases (PubMed, Embase, Web of Science, Scopus, CENTRAL) up to December 20, 2025.
- A frequentist random-effects network meta-analysis (NMA) of seven randomized controlled trials (RCTs) involving 12,469 participants was performed.
- Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated, and treatments were ranked using P-scores.
Main Results:
- De-escalation therapy showed a potential reduction in bleeding compared to DOAC dual therapy (RR 0.50; 95% CI 0.30-0.82), though this finding requires cautious interpretation due to limited evidence.
- Warfarin with VKAs (VKA dual and triple therapy) significantly increased bleeding risk (RR 1.33-1.42) and intracranial hemorrhage (RR 2.95) compared to DOAC dual therapy.
- No significant differences were observed in all-cause death, myocardial infarction, or stent thrombosis among the strategies, with wide confidence intervals indicating no statistically detectable differences.
Conclusions:
- A de-escalation approach (short-course dual therapy followed by DOAC monotherapy) may offer a bleeding benefit over DOAC dual therapy in AF patients undergoing PCI, but requires further validation.
- Warfarin-based regimens, especially triple therapy, were associated with increased bleeding and intracranial hemorrhage, highlighting potential safety concerns.
- Given the low event rates for ischemic outcomes, observed similarities across strategies should not be interpreted as equivalence, emphasizing the need for careful patient selection and monitoring.
Background:
Optimal antithrombotic management for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) or coronary artery disease (CAD) remains challenging because bleeding and ischemic risks compete. We compared five strategies: de-escalation (short-course dual therapy followed by DOAC monotherapy), VKA triple therapy, VKA dual therapy, DOAC dual therapy, and DOAC triple therapy.
Methods:
We searched PubMed, Embase, Web of Science, Scopus, and CENTRAL from inception to 20 December 2025 for randomized controlled trials (RCTs). We performed a frequentist random-effects network meta-analysis (NMA) and reported risk ratios (RRs) with 95% confidence intervals (CIs). Treatments were ranked using P-scores. The primary outcomes were all-cause death and ISTH major or clinically relevant non-major bleeding.
Results:
Seven RCTs (12,469 participants) were included. For International Society on Thrombosis and Haemostasis (ISTH) major or clinically relevant non-major bleeding (CRNMB), de-escalation reduced bleeding compared with DOAC dual therapy (RR 0.50; 95% CI 0.30-0.82); this estimate is informed by a single Japanese trial (OPTIMA-AF) and should be interpreted cautiously. In contrast, VKA dual therapy (RR 1.33; 95% CI 1.02-1.72) and VKA triple therapy (RR 1.42; 95% CI 1.21-1.66) increased bleeding risk versus DOAC dual therapy; DOAC triple therapy did not differ significantly. There were no significant differences in all-cause death, myocardial infarction, or stent thrombosis among strategies. However, VKA triple therapy increased intracranial hemorrhage (RR 2.95; 95% CI 1.32-6.56) and VKA dual therapy increased stroke (RR 2.72; 95% CI 1.15-6.45) compared with DOAC dual therapy.
Conclusions:
In AF patients undergoing PCI, a strategy of short-course dual therapy followed by DOAC monotherapy may reduce bleeding compared with DOAC dual therapy, but evidence is limited and derives from one randomized trial. VKA-based regimens-particularly VKA triple therapy-consistently increased bleeding and intracranial hemorrhage. For ischemic outcomes, event rates were low and confidence intervals were wide; therefore, findings should be interpreted as no statistically detectable differences rather than equivalence.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins